Added value of hepatobiliary phase gadoxetic acid-enhanced MRI for diagnosing hepatocellular carcinoma in high-risk patients

Table 6 Results of the univariate analysis of the magnetic resonance imaging findings for the diagnosis of hepatocellular carcinoma n (%)

MRI findings	All lesions (n = 105)			Lesions excluding cysts and hemangiomas (n = 89)
	HCC (n = 59)	Not HCC (n = 46)	P value	HCC (n = 59)	Not HCC (n = 30)	P value
Fat metamorphosis	10 (16.9)	2 (4.3)	0.061	10 (16.9)	2 (6.7)	0.190
Hyperintensity on T2-weighted images	39 (66.1)	18 (39.1)	0.007	39 (66.1)	2 (6.7)	< 0.001
Arterial enhancement	52 (88.1)	15 (32.6)	< 0.001	52 (88.1)	9 (30)	< 0.001
Arterial enhancement and washout on venous or equilibrium phase images	47 (79.7)	1 (2.2)	< 0.001	47 (79.7)	1 (3.3)	< 0.001
Hypointensity on 20-min hepatobiliary phase images	55 (93.2)	30 (65.2)	0.001	55 (93.2)	14 (46.7)	< 0.001
Arterial enhancement and no/partial uptake on 20-min hepatobiliary phase images	49 (83.1)	8 (17.4)	< 0.001	49 (83.1)	2 (6.7)	< 0.001

HCC: Hepatocellular carcinoma. MRI: Magnetic resonance imaging.